Back to Journals » OncoTargets and Therapy » Volume 8

Profile of bevacizumab and its potential in the treatment of cervical cancer

Authors Fisher C, Schefter T

Received 1 July 2015

Accepted for publication 19 September 2015

Published 19 November 2015 Volume 2015:8 Pages 3425—3431

DOI https://doi.org/10.2147/OTT.S73251

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati

Christine M Fisher, Tracey E Schefter

Department of Radiation Oncology, University of Colorado, Denver, CO, USA

Abstract: Blocking angiogenesis is an effective antitumor strategy proven in many disease sites. Anti-angiogenic therapies are fulfilling the promise of improved outcomes in cervical cancer as demonstrated in several recent trials. With its overall survival improvement in metastatic or recurrent cervical cancer, a frame shift in the management of these patients has occurred. The US Food and Drug Administration approval of bevacizumab in advanced cervical cancer has led to national guidelines, including the US National Comprehensive Cancer Network guidelines for cervical cancer, including systemic regimens containing bevacizumab as first line combination therapy. Future trials will build on this anti-angiogenesis backbone via targeting additional novel pathways and potentially leading to further improved outcomes in cervical cancer.

Keywords: HPV, anti-angiogenic therapy, cervix, arastin, VEGF, metastatic, recurrent

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]